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C hronic obstructive pulmonary disease (COPD) is treatable and preventable chronic disease charac-
terized by persistent airflow limitation that is usually 
progressive and associated with an increased inflamma-
tory response to noxious particles and gases [1].  An 
interaction between genetic susceptibility and environ-
mental exposure has a role in the development of 
COPD [2].  Cigarette smoking is the most important 
etiologic factor.  It is reported that nearly 50% of smok-
ers will develop COPD [3].  The reduction and elimina-
tion of exposure to risk factors have great importance 
for the prevention of COPD progression.
The exacerbation of COPD is defined as an acute 
event characterized by a worsening of respiratory symp-
toms that is beyond normal day-to-day variations and 
leads to a change in medication [1].  Exacerbations are 
an important cause of mortality and morbidity in COPD 
patients [4-6].  The frequency of exacerbations varies 
from patient to patient,  and frequent exacerbations 
have a negative impact on an individual’s quality of life 
[7].  The main determinants of frequent exacerbations 
(i.e.,  ≥ 2 per year) are prior treated exacerbations and an 
increase in airflow limitation.
Clinical failure after the treatment of a COPD exac-
erbation is common.  Impaired lung function,  dyspnea 
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We evaluated the frequency of exacerbations and hospitalizations in chronic obstructive pulmonary disease 
(COPD) patients who continue to smoke.: We retrospectively analyzed the medical records of the COPD 
patients treated in Chest Diseases Clinic of Kocaeli University School of Medicine in 2007-2013.  Their demo-
graphic characteristics,  smoking status (non-smoker,  current smoker,  ex-smoker),  Charlson Comorbidity 
Index (CCI),  and history of COPD exacerbation and hospitalizations were evaluated.  The cases of 120 patients 
(11 females,  9.2%; 109 males,  90.8%) were analyzed.  Sixteen (13.3%) of the patients were current smokers,  
and 104 patients were ex-smokers (n = 99) or non-smokers (n = 5).  The mean age was 69.7 ± 7.9 years in the 
ex-smokers and 62.94 ± 6.8 years in the current smokers.  There were no significant differences between the cur-
rent and ex-smokers regarding smoking history,  FEV1 value,  frequencies of exacerbations and hospitalization 
per year,  or duration of follow-up.  The initial stage of the COPD and the frequency of exacerbations were sig-
nificantly correlated (p= 0.003).  The CCI values were significantly higher in the ex-smokers compared to current 
smokers (p= 0.02).  A correlation analysis of age,  hospitalization and CCI revealed that age was significantly 
correlated with the hospitalization rate (p= 0.02).  Older age and the presence of comorbidities in ex-smokers 
might explain the similar rates of exacerbation and hospitalization between these current and ex-smokers.
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and active smoking have been associated with clinical 
failure [6].  However,  Yip et al.  reported that the active 
smoking rate of COPD patients was similar among 
patients with a single hospital admission versus those 
with multiple hospital admissions [8],  and Alcazar et al.  
indicated that they found no significant difference in the 
active smoking rate based on previous hospitalizations 
[9].
Smoking is known as risk factor for the develop-
ment of COPD,  and in recent guidelines smoking ces-
sation is emphasized as a key intervention for all COPD 
patients who continue to smoke [1].  However,  the 
similarities and differences in the clinical presentation 
of COPD patients according to their smoking status 
have not been fully described [10].  The complete eluci-
dation of a risk factor is the first step in the manage-
ment and early prevention strategies in COPD patients,  
as this may reduce the frequency of exacerbations and 
hospitalizations.  We conducted the present study to 
evaluate the role of active smoking in the frequency of 
exacerbations and hospitalizations among patients with 
COPD.
Patients and Methods
We retrospectively analyzed the medical records of 
the consecutive COPD patients who were treated in 
Chest Diseases Clinic of Kocaeli University School of 
Medicine in Turkey in the years 2007-2013.  We deter-
mined each patient’s demographic characteristics,  
smoking history,  Charlson Comorbidity Index (CCI) 
score,  initial forced expiratory volume in 1 sec (FEV1) 
value,  stage of COPD,  duration of follow-up,  and his-
tory of exacerbations and hospitalizations.  Generally,  
hospitalization due to respiratory symptoms of COPD is 
regarded as a severe exacerbation.  We therefore included 
the number of hospitalizations in the exacerbation 
number.  The presence of a post-bronchodilator FEV1/
forced vital capacity (FVC) value < 0.70 confirmed the 
presence of airflow limitation according to the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
guideline [1].
Smoking history. We defined smoking history of 
the patients according to consumption of cigarette per 
day and number of year by self-reports of patients on a 
questionnaire [Pack years = (Number of cigarettes per 
day/20) × Number of years].  The consumption of other 
tobacco products were not considered.
Non-smoker: A patient who had never smoked on a 
regular basis.
Ex-smoker: A regular smoker who had a smoking his-
tory at least 10 pack years and who had stopped smok-
ing > 6 months before admission.
Current smoker: A patient with a smoking history of at 
least 10 pack years and who had smoked regularly 
within 6 months.
Severity of COPD. We classified the severity of 
the patients’ COPD according to their post-bronchodi-
lator FEV1 values,  as follows:
GOLD 1: Mild FEV1,  ≥ 80% of the predicted value
GOLD 2: Moderate,  50% ≤ FEV1 < 80% predicted
GOLD 3: Severe,  30% ≤ FEV1 < 50% predicted
GOLD 4: Very severe,  FEV1 < 30% predicted
Exacerbation. We defined ‘exacerbation of 
COPD’ as an acute event characterized by a worsening 
of the patient’s respiratory symptoms that was beyond 
normal day-to-day variations and led to a change in 
medication [1].  The number of exacerbations within the 
prior 12 months for each COPD patient was deter-
mined.
The Charlson Comorbidity Index (CCI). We 
evaluated the patients’ comorbidities by using the pre-
defined list of medical conditions that is used to calcu-
late the CCI (both unadjusted and age-adjusted) [11].  
The CCI encompasses 19 medical conditions weighted 
1-6,  with total scores ranging from 0 to 37.  From the 
weighted conditions,  a sum score can be tallied to yield 
the total comorbidity score.  The CCI can be further 
adapted to account for increasing age.  In the validation 
phase of the CCI in the present study,  age was found to 
be an independent risk factor for death from a comor-
bid condition.  To account for the effects of increasing 
age,  one point can be added to the CCI score for each 
decade of life over the age of 50 [12].
A CCI score of 1 indicates the absence of comorbid-
ities other than COPD.  Patients with a CCI score of 2 
were classified as having low comorbidity,  and those 
with scores ≥ 3 were classified as having high comorbid-
ity.
Exclusion criteria. Patients with other lung dis-
eases such as tuberculosis,  bronchiectasis and intersti-
tial lung disease were excluded from the present analy-
ses,  as were patients who had an airflow limitation due 
to abnormalities in the large airways.
Statistical analysis. We used the Statistical 
Package for Social Sciences (SPSS 16.0) program for the 
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statistical analyses of the data.  Categorical variables 
were recorded as percentages,  and numeric variables 
were recorded as mean and standard deviation (SD).  
Compliance with the normal distribution of data was 
evaluated by Shapiro-Wilk test.  The chi-square test was 
used for comparing non-parametric variables.  A 
p-value < 0.05 was considered significant.
Results
The cases of a total of 120 patients (11 females,  
9.2%; 109 males,  90.8%) were analyzed.  The mean 
duration of follow-up was 3.2 ± 1.7 years.  Sixteen 
(13.3%) of the patients were current smokers; 5 (4.2%) 
were non-smokers,  and 99  (82.5%) were ex-smokers.  
The percentages of these three categories are illustrated 
in Fig. 1.
The patients’ characteristics and frequency of exac-
erbations and hospitalizations according to the patients’ 
smoking status are summarized in Table 1.  The mean 
age of the ex-smokers was 69.7 ± 7.9 years; that of the 
current smokers was 62.94 ± 6.8 years,  and that of the 
non-smokers was 66.2 ± 6.8 years.  The mean ages of 
current and ex-smokers were significantly different 
(p = 0.005).  There were no significant differences 
between the current and ex-smokers in smoking pack-
years,  FEV1 values,  frequency of exacerbations,  fre-
quency of hospitalizations in the prior 12 months,  or 
the duration of follow-up.  Stage 4 COPD was noted in 
7 (7.1%) of the ex-smokers but in none of the current 
smokers.
Significant correlations were revealed between the 
initial stage of COPD and the frequency of the exacer-
bations (p = 0.003,  initial stage of COPD and the fre-
quency of exacerbations peryear (p = 0.001),  and initial 
stage of COPD and the frequency of hospitalizations per 
year,  ︲(p = 0.000)) (Fig. 2).
The CCI scores and age-adjusted CCI scores were 
significantly higher in the ex-smokers compared to the 
current smokers (p = 0.02 and p = 0.002,  respectively;  
Table 1,  Fig. 3A,  B).
In a correlation analysis of the factors of age,  hospi-
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Fig. 1　 The 120 COPD patientsʼ smoking status.







Age (yrs) 66.2±6.8 62.94±6.8a 69.7±7.9a 0.005
Male/female (n,  %) 3 (60%)/2 (40%) 14 (87.5%)/2 (12.5%) 92 (92.9%)/7 (7.1%)
Smoking package of years
Pack years= (Number of cigarettes per day/20) X 
Number of years
0 43.4±25.7 47.2±27.7 0.6
No. of exacerbations 1.8±1.5 1.5±2.1 1.8±2.2 0.6
Duration of follow-up (months; mean) 3.2±1.1 2.9±1.7 3.2±1.7 0.6
No. of hospitalizations 0.2±0.4 0.69±1.4 0.79±1.8 0.8
No. of hospitalizations during the prior 12 months 0.1±0.2 0.23±0.5 0.21±0.4 0.9
CCI 1.4±0.5 1.25±0.4b 1.7±0.8b 0.02
CCI (age-adjusted) 4.4±1.1 4.0±0.96c 4.96±1.2c 0.002
FEV1 initial (l) 1.73±0.5 1.71±0.4 1.68±0.7 0.8
FEV1 initial % 68.6±16.6 56.8±12.2 57.39±19.4 0.9
CCI,  Charlson Comorbidity Index; FEV1,  forced expiratory volume in 1 sec.
Comparison of groups: Statistically signiﬁcant diﬀerences (p<0.05) were summarized.
Age,  aCurrent smokers and ex-smokers,  p＝0.005; CCI,  bCurrent smokers and ex-smokers,  p＝0.02; CCI age adjusted,  cCurrent smokers 
and ex-smokers,  p＝0.002.
talization rate and CCI scores,  we found that age was 
significantly correlated with the hospitalization rate 
(p = 0.02).  There were 90 hospitalizations among the 
total patient series during the study period,  and 80% of 
these episodes occurred in patients > 65 years old.  No 
correlation was found between CCI scores and the hos-
pitalization rate,  but there were 63 patients (52.5%) 
who had no comorbid condition other than COPD.  We 
also noted that there were 50 hospitalizations in the 
remaining 57 patients who had higher CCI scores.
Discussion
Our retrospective analysis of 120 patients with 
COPD revealed that the rate of active smoking was low 
in this patient series,  and it was lower than those of 
previous studies as summarized below.  We found no 
significant difference in the numbers of exacerbation 
episodes or hospitalizations between the current smok-
ers and ex-smokers.
COPD is one of the most important causes of mor-
tality and morbidity throughout the world.  In older 
individuals in the United States,  it is among the 10 most 
important diseases causing hospitalizations and death,  
with a prevalence that is increasing day by day [13].  
COPD is more common in men than women due to 
males’ higher rates of smoking and occupational expo-
sure.  However,  the increase in cigarette smoking 
among women and their increasing presence in danger-
ous work environments have led to an increase in the 
prevalence of COPD in women [14].  There was also a 
male dominance in our study; only 11% of the patients 
were female.
Some of the risk factors of COPD are well known:-
smoking,  occupational exposure,  air pollution,  airway 
hyper-responsiveness,  and genetic variations [15].  The 
assessment of risk factors is important in the manage-
ment of COPD patients,  and smoking is the most 
important etiologic factor.  However,  the exposure to 
passive smoking and biomass fuel used for heating are 
discriminative for women among non-smoker COPD 
patients [16].  In our study,  4.2% of the patients were 
non-smokers whereas 95.8% of the patients had a 
smoking history (13.3% of the patients were current 
smokers,  plus 82.5% of the patients were ex-smokers).  
Forty percent of the non-smoker patients were female 
and they had biomass exposure.  Although smoking 
cessation is the first step in the management of COPD,  
active smoking rates are still high in COPD patients.  In 
a previous study,  many patients continued to smoke 
after the diagnosis of COPD (16.8%) or lung cancer 
(15.1%) [16].  The active smoking prevalence varies in 






















Fig. 2　 The distribution of disease severity according to smoking 
status (%).  See the Patients and Methods section for the explana-










































Fig. 3　 A: The distribution of CCI scores according to smoking 
status (n).  CCI score of 1＝absence of comorbidity other than 
COPD.  CCI score of 2＝ low comorbidity (COPD＋1 comorbidity).  
CCI score of 3＝high comorbidity (COPD＋ ≥2 comorbidities).  
B: Age-adjusted CCI scores according to smoking habits (n).
different working groups.  In the ESFERA study of 
COPD patients conducted in Spain,  the active smoking 
rate was 19.3% [6].  An evaluation of the hospitaliza-
tions due to COPD exacerbation revealed active smok-
ing in 33% of the patients [16].  The active smoking rate 
in the present study (13.3%) is relatively low.  In our 
department,  we have a separate outpatient smoking 
cessation clinic and an outpatient COPD clinic designed 
to treat these two groups of individuals separately.  The 
major goals of our COPD management policy are the 
education of the patients about both COPD and smok-
ing cessation.  This may explain the lower rate of current 
smokers in our study population.
It has been reported that respiratory symptoms,  the 
annual decrease of FEV1 values and mortality rates are 
higher in smokers than nonsmokers [1].  The most 
effective strategy to prevent declining lung function 
among COPD patients is smoking cessation [17].  
Smoking cessation should be considered for all COPD 
patients regardless of the level of disease severity [1].
Exacerbations of COPD are the most frequent cause 
of morbidity,  hospital admissions and mortality in 
COPD patients [17].  The early detection and effective 
treatment of exacerbations are key factors that may 
reduce the likelihood of hospital admissions and pre-
vent re-admissions [18].  However,  clinical failure after 
the treatment of COPD is common,  and active smok-
ing,  impaired lung function,  and severe dyspnea are 
associated with clinical failure [6].  Re-admissions are 
associated with the degree of lung function impairment 
(as shown by GOLD grades),  lower FEV1 and the fre-
quency of previous exacerbations [19-21].  As in prior 
studies,  our present analysis showed that the initial 
stage of the disease (according to GOLD stage) and the 
frequency of exacerbations are correlated (p = 0.003).  
However,  there were no significant differences in FEV1 
values,  the frequency of exacerbations or the number of 
hospitalizations in the prior 12 months between the 
current smokers and ex-smokers in our series.  We sus-
pect that the older age and presence of comorbidities in 
the ex-smoker group and the absence of stage 4 disease 
in the current smoker group might explain the similar 
rates of exacerbation and hospitalization between the 
current and ex-smokers.
COPD is a chronic,  systemic disease with comor-
bidities that affect respiratory symptoms,  worsen the 
prognosis,  and increase the exacerbation frequency and 
mortality [22 , 23].  There is a causal relationship between 
COPD and comorbidities that influences the clinical 
course of the disease [24].  The severity and prognosis of 
exacerbation is best predicted by the presence or 
absence of significant comorbid conditions [17].  
Several reports suggest that cardiovascular disease is 
associated with the exacerbation of COPD [25 , 26].
The CCI,  which is a predefined list of medical con-
ditions used to calculate a comorbidity score,  has good 
reliability and an excellent correlation with mortality,  
and it is easily modified,  particularly to account for the 
effect of age.  The CCI is preferred for its ease of use,  
short rating time,  extractability from other indices,  and 
widespread use [10].  The CCI scores of the present 
study’s ex-smokers were significantly higher compared 
to those of the current smokers.  We speculate that the 
higher comorbidity scores in the ex-smokers compared 
to the current smokers could be explained by the need 
to quit smoking based on the fear of a decreased quality 
of life related to intense comorbidities.
Our correlation analysis regarding patient age,  hos-
pitalization and CCI revealed that age is correlated with 
the rate of hospitalizations,  which is not unexpected 
since 80% of the hospitalizations occurred in patients 
> 65 years old.  However,  there was no correlation 
between CCI scores and hospitalization.  Nearly half of 
the study group (47.5%) had at least one comorbid con-
dition other than COPD,  and patients with high CCI 
scores accounted for 55.6% of the hospitalizations.  
These findings suggest that the CCI is an important fac-
tor for hospitalization in COPD patients.  We suspect 
that the limited number of patients with multiple 
comorbid conditions in this study might be responsible 
for the nonsignificant relationship between CCI scores 
and hospitalization.
Limitations of the study. There are several limita-
tions to our study that should be considered.  First,  it 
was a retrospective investigation,  and the data collec-
tion was based on medical records.  Second,  the num-
ber of current smokers was low compared to that of 
ex-smokers.  Third,  there was no current smoker in the 
stage 1 or stage 4 COPD groups.  It is possible that stage 
4 COPD patients are unable to smoke because of their 
disease severity,  and we suspect that these patients ‘stop 
smoking’ simply because they cannot smoke.  This may 
explain why there was no current smoker in the stage 4 
COPD group.  Since there were no current smokers in 
the stage 1 or 4 COPD groups,  our assessment regard-
ing smoking history concerned mostly stage 2 and 3 
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patients.  This nonhomogeneous distribution of smok-
ers among the patient groups may have affected our 
results concerning the relationship between current 
smoking and the exacerbation and hospitalization rates 
of COPD patients.  Future studies are needed to deter-
mine whether our results are also applicable for all 
stages of COPD patients.
Fourth,  the goals of COPD assessment are to deter-
mine the severity of the disease,  its impact on a patient’s 
health status and the risk of future events such as exac-
erbation,  hospitalization and death.  However,  due to 
the retrospective nature of this study,  we could not 
determine the patients’ health status by using,  for 
example,  the modified Medical Research Council 
(mMRC) Questionnaire or the COPD assessment test 
(CAT),  and we could not evaluate the new classifica-
tion of COPD.  The severity of the patients’ COPD was 
thus classified by using only post-bronchodilator FEV1 
values.  Lastly,  the gender distribution among our 
patient groups was not homogenous since smoking was 
more prevalent in male than females in our country.
It is accepted that assessments of COPD require a 
combination of parameters including pulmonary func-
tions,  exacerbation history,  severity of symptoms and 
comorbid conditions.  Our findings suggest that the 
implementation of a questionnaire inquiring about 
comorbidities (such as the CCI) in a patient’s follow-up 
might be helpful to predict the hospitalization and exac-
erbation risks in COPD patients,  since the presence of 
comorbid conditions was shown to be a more important 
factor in exacerbations than current smoking.
In conclusion,  the current smoking rate in our pres-
ent series of 120 COPD patients was lower than those of 
previous studies.  We observed no significant difference 
in the numbers of exacerbations or hospitalizations 
between the current smokers and ex-smokers.  The older 
age and the presence of comorbidities in the ex-smokers 
group might explain the similar rates of exacerbations 
and hospitalizations between the current and former 
smokers.  Further prospective trials including more 
patients both in ex-smoker and current smoker arms are 
needed to clarify the relationships among exacerbation,  
smoking status and comorbidities in COPD patients.
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